As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Positive opinions based on significant survival benefit
The product is backed by required scientific proof and comparative bioequivalence studies
Post the sale, Patel family has become the single largest promoter shareholder in the company
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
Subscribe To Our Newsletter & Stay Updated
